Maximum Oral Hydralazine Dose
The maximum recommended oral dose of hydralazine is 300 mg per day in divided doses 1, 2, 3.
Dosing Framework
Standard Dosing Regimen
For chronic heart failure with reduced ejection fraction (HFrEF), the evidence-based dosing is:
- Initial dose: 25-50 mg three to four times daily (or fixed-dose combination: 37.5 mg hydralazine/20 mg isosorbide dinitrate three times daily)
- Target dose: 300 mg hydralazine total daily in divided doses (or fixed-dose combination: 75 mg hydralazine/40 mg isosorbide dinitrate three times daily) 1, 2
In clinical trials for heart failure, the mean achieved dose was approximately 175 mg hydralazine daily when combined with isosorbide dinitrate 1, 2.
Pediatric Dosing
For pediatric patients:
- Initial dose: 0.75 mg/kg body weight daily in four divided doses
- Maximum dose: 7.5 mg/kg or 200 mg daily, whichever is lower 3
Critical Dosing Considerations
Acetylator Status Impact
Acetylator phenotype significantly affects hydralazine bioavailability and required dosing:
- Slow acetylators: Achieve therapeutic effect at lower doses (D50 = 0.87 mg/kg) due to higher bioavailability (26.2% ± 13.0%)
- Fast acetylators: Require higher doses (D50 = 1.68 mg/kg) due to lower bioavailability (9.9% ± 6.0%) 4, 5
This explains the wide dosing range (75-300 mg/day) needed in clinical practice 6.
Dose-Response Characteristics
Hydralazine exhibits saturable first-pass metabolism, meaning:
- At low doses (≤225 mg/day), acetylation capability is the primary determinant of systemic availability
- At higher doses (225-300 mg/day), saturation of first-pass metabolism occurs, resulting in disproportionate increases in drug exposure 5
Hemodynamic response is dose-dependent:
- 50 mg: No significant hemodynamic effects
- 75 mg: Modest improvement (19% decrease in systemic vascular resistance)
- 100 mg: Substantial improvement (31% decrease in systemic vascular resistance, +0.60 L/min/m² cardiac index)
- 150-200 mg: Required for non-responders to 100 mg doses 6
Renal Function Adjustment
Duration of action is significantly prolonged in renal impairment:
- Creatinine clearance <35 mL/min: 14.3 ± 1.4 hours duration
- Normal renal function: 7.9 ± 0.5 hours duration 6
Dosing interval should be extended in renal impairment to avoid drug accumulation, though the maximum daily dose remains 300 mg.
Important Safety Caveats
Contraindications to Maximum Dosing
Do not use maximum doses in patients with:
- Suspected coronary artery disease (risk of myocardial ischemia/infarction) 3
- Mitral valvular disease (may increase pulmonary artery pressure) 3
- Advanced renal damage (use with caution) 3
Monitoring Requirements
At doses approaching 300 mg/day, monitor for:
- Peripheral neuritis (paresthesia, numbness, tingling) - consider pyridoxine supplementation 3
- Blood dyscrasias (complete blood counts periodically) 3
- Lupus-like syndrome (antinuclear antibody titers before and during prolonged therapy) 3
Clinical Context Matters
For hypertensive emergencies (IV route): Maximum initial IV dose is 20 mg, repeated every 4-6 hours as needed 7, 8, 7. However, hydralazine is not a first-line agent for acute hypertensive emergencies due to unpredictability of response and prolonged duration of action 7, 8, 7.
For resistant hypertension: Hydralazine 25 mg three times daily, titrated upward to maximum dose, is recommended only at Step 5 of the treatment algorithm, after optimizing other agents 9.
For pregnancy-related hypertension: Maximum cumulative IV dose is 20 mg, with oral immediate-release nifedipine or labetalol preferred over hydralazine 10, 11.